X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9296) 9296
Publication (1260) 1260
Book Review (76) 76
Book Chapter (65) 65
Dissertation (53) 53
Conference Proceeding (22) 22
Government Document (5) 5
Book / eBook (2) 2
Data Set (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5504) 5504
humans (4415) 4415
pi3k (4251) 4251
animals (3130) 3130
oncology (2669) 2669
apoptosis (2624) 2624
phosphatidylinositol 3-kinases - metabolism (2477) 2477
akt (2088) 2088
proto-oncogene proteins c-akt - metabolism (2062) 2062
cancer (2014) 2014
signal transduction (1868) 1868
cell line, tumor (1769) 1769
mice (1747) 1747
activation (1728) 1728
cell biology (1701) 1701
signal transduction - drug effects (1657) 1657
expression (1591) 1591
phosphorylation (1506) 1506
phosphatidylinositol 3-kinases - antagonists & inhibitors (1495) 1495
female (1469) 1469
pi3k/akt (1444) 1444
biochemistry & molecular biology (1421) 1421
kinases (1362) 1362
male (1251) 1251
proteins (1197) 1197
pharmacology & pharmacy (1053) 1053
apoptosis - drug effects (1029) 1029
pathway (950) 950
mtor (917) 917
growth (898) 898
1-phosphatidylinositol 3-kinase (879) 879
cell proliferation - drug effects (865) 865
research (833) 833
inhibition (810) 810
proliferation (798) 798
antineoplastic agents - pharmacology (795) 795
rats (778) 778
cell proliferation (765) 765
akt protein (757) 757
analysis (749) 749
pi3k/akt pathway (731) 731
breast cancer (730) 730
tumors (724) 724
metastasis (705) 705
article (698) 698
protein kinase inhibitors - pharmacology (692) 692
health aspects (691) 691
gene expression (690) 690
cells (680) 680
tor serine-threonine kinases - metabolism (671) 671
cell cycle (654) 654
enzyme inhibitors - pharmacology (651) 651
phosphatidylinositol 3-kinase (651) 651
mutation (644) 644
phosphatidylinositol 3-kinases - genetics (642) 642
cell growth (627) 627
morpholines - pharmacology (626) 626
care and treatment (623) 623
genetic aspects (611) 611
medicine, research & experimental (610) 610
phosphoinositide 3-kinase (607) 607
proto-oncogene proteins c-akt - antagonists & inhibitors (578) 578
kinase (574) 574
pten (572) 572
cells, cultured (571) 571
chemotherapy (562) 562
survival (556) 556
in-vitro (538) 538
tor serine-threonine kinases - antagonists & inhibitors (536) 536
breast-cancer (535) 535
chromones - pharmacology (530) 530
signaling pathway (528) 528
chemistry, medicinal (517) 517
development and progression (505) 505
resistance (505) 505
inflammation (490) 490
blotting, western (488) 488
autophagy (487) 487
cell survival - drug effects (473) 473
inhibitors (466) 466
signal transduction - physiology (465) 465
cancer therapies (461) 461
nf-kappa-b (457) 457
oxidative stress (454) 454
dose-response relationship, drug (453) 453
middle aged (449) 449
neurosciences (437) 437
cell line (428) 428
rapamycin (428) 428
phosphorylation - drug effects (425) 425
studies (425) 425
migration (416) 416
therapy (414) 414
proto-oncogene proteins c-akt - genetics (412) 412
antineoplastic agents - therapeutic use (411) 411
pi3k/akt/mtor pathway (409) 409
physiological aspects (403) 403
mammalian target (402) 402
xenograft model antitumor assays (399) 399
in-vivo (388) 388
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9324) 9324
Japanese (17) 17
Korean (17) 17
Chinese (15) 15
French (8) 8
German (4) 4
Spanish (4) 4
Polish (3) 3
Turkish (3) 3
Russian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine... 
ACTIVATION | NVP-BYL719 | PIK3CA MUTATIONS | PI3K | ONCOLOGY | PHOSPHATIDYLINOSITOL 3-KINASE | GROWTH | ESTROGEN DEPRIVATION | RESISTANCE | ALPHA | TUMORS | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Safety engineering | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Breast | Antitumor activity | Tumors | DNA sequencing | Cancer
Journal Article
Cellular and Molecular Life Sciences, ISSN 1420-682X, 3/2016, Volume 73, Issue 5, pp. 985 - 1001
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2013, Volume 19, Issue 1, pp. 279 - 290
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2013, Volume 133, Issue 9, pp. 2089 - 2101
The RAS/RAF/MEK/MAPK and the PTEN/PI3K/AKT/mTOR pathways are key regulators of proliferation and survival in human cancer cells. Selective inhibitors of... 
lung cancer | colorectal cancer | combination of molecular targeted therapies | MEK inhibitors | SIGNALING PATHWAYS | ACTIVATION | RAS | AZD6244 | ARRY-142886 | IDENTIFICATION | PI3K | ONCOLOGY | SELUMETINIB | KRAS | TUMOR-GROWTH | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Gene Expression Profiling | TOR Serine-Threonine Kinases - antagonists & inhibitors | Colorectal Neoplasms - drug therapy | Biomarkers, Tumor - metabolism | Female | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Colorectal Neoplasms - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | PTEN Phosphohydrolase - metabolism | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Cell Cycle - drug effects | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Colorectal cancer | Tumors | Chemotherapy | Pharmacology | Kinases | Lung cancer
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 22, pp. 3390 - 3397
Journal Article
MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 05/2014, Volume 13, Issue 5, pp. 1044 - 1053
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 512 - 518
Journal Article
Liver International, ISSN 1478-3223, 05/2013, Volume 33, Issue 5, pp. 780 - 793
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2607 - 2619
Checkpoint inhibitors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alterations and a T-cell-inflamed phenotype. One... 
HEAD | RESPONSES | ONCOLOGY | IMMUNE SUPPRESSION | REGULATORY T-CELLS | PI3K-GAMMA | BLOCKADE | EXPRESSION | CARCINOMA | NECK-CANCER | TUMOR MICROENVIRONMENT | Neoplasms - metabolism | Immunomodulation - drug effects | Myeloid-Derived Suppressor Cells - drug effects | Lymphocyte Activation - immunology | Isoquinolines - pharmacology | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Epitopes, T-Lymphocyte - immunology | Myeloid-Derived Suppressor Cells - metabolism | Disease Models, Animal | Myeloid-Derived Suppressor Cells - immunology | Purines - pharmacology | Antibodies, Monoclonal - pharmacology | Lymphocytes, Tumor-Infiltrating - drug effects | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Neoplasms - drug therapy | Tumor Microenvironment - immunology | Animals | B7-H1 Antigen - antagonists & inhibitors | Lymphocyte Activation - drug effects | Neoplasms - immunology | Survival Analysis | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Neoplasms - pathology | Lymphocytes, Tumor-Infiltrating - immunology | Cell culture | Myeloid cells | Effectiveness | Cell survival | CD8 antigen | Effector cells | Lymphocytes T | Inflammation | Suppressor cells | Recruitment | Immunosuppression | Inhibitors | Immune checkpoint | Lymphocytes | PD-L1 protein | Isoforms | Head and neck | Neck | Head & neck cancer | Inhibition | Cancer | Immune system | immunosuppression | MDSC | IPI-145 | PI3K | head and neck cancer
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 07/2018, Volume 132, Issue 3, pp. 293 - 306
Because both phosphatidylinositol 3-kinase delta (PI3K delta) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to... 
SELECTIVE INHIBITOR | PI3K | SIGNALING PATHWAY | IL-10 LEVELS | IDELALISIB | SUBTYPES | INCB039110 | BLOCKADE | HEMATOLOGY | Lymphoid Neoplasia
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 08/2014, Volume 90, Issue 3, pp. 197 - 207
While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous... 
mTOR | AKT | SQCLC | PI3K | NSCLC | MAMMALIAN TARGET | I PI3K INHIBITOR | ONCOGENE MUTATIONS | AKT INHIBITOR | ANTITUMOR-ACTIVITY | DOSE-ESCALATION | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | ADVANCED NSCLC | PHASE-I | MTOR INHIBITOR | Lung Neoplasms - drug therapy | TOR Serine-Threonine Kinases - metabolism | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Enzyme Inhibitors - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Enzyme Inhibitors - adverse effects | Molecular Targeted Therapy - adverse effects | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - metabolism | Enzyme Inhibitors - therapeutic use | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Journal Article